Mycenax Biotech Statistics

Total Valuation

Mycenax Biotech has a market cap or net worth of TWD 8.69 billion. The enterprise value is 9.20 billion.

Market Cap	8.69B
Enterprise Value	9.20B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Mycenax Biotech has 206.62 million shares outstanding. The number of shares has increased by 0.99% in one year.

Current Share Class	n/a
Shares Outstanding	206.62M
Shares Change (YoY)	+0.99%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	1.17%
Owned by Institutions (%)	0.20%
Float	112.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.87
PB Ratio	4.14
P/TBV Ratio	4.22
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.16
EV / Sales	13.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.85

Financial Position

The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.44.

Current Ratio	1.29
Quick Ratio	0.78
Debt / Equity	0.44
Debt / EBITDA	n/a
Debt / FCF	-1.68
Interest Coverage	-19.77

Financial Efficiency

Return on equity (ROE) is -22.84% and return on invested capital (ROIC) is -9.66%.

Return on Equity (ROE)	-22.84%
Return on Assets (ROA)	-8.42%
Return on Capital (ROIC)	-9.66%
Revenue Per Employee	1.74M
Profits Per Employee	-1.39M
Employee Count	387
Asset Turnover	0.18
Inventory Turnover	9.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.32% in the last 52 weeks. The beta is 1.06, so Mycenax Biotech's price volatility has been similar to the market average.

Beta (5Y)	1.06
52-Week Price Change	+20.32%
50-Day Moving Average	46.83
200-Day Moving Average	47.81
Relative Strength Index (RSI)	40.13
Average Volume (20 Days)	923,855

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mycenax Biotech had revenue of TWD 672.85 million and -536.33 million in losses. Loss per share was -2.61.

Revenue	672.85M
Gross Profit	-283.22M
Operating Income	-493.03M
Pretax Income	-527.66M
Net Income	-536.33M
EBITDA	-234.17M
EBIT	-493.03M
Loss Per Share	-2.61

Full Income Statement

Balance Sheet

The company has 403.62 million in cash and 917.12 million in debt, giving a net cash position of -513.50 million or -2.49 per share.

Cash & Cash Equivalents	403.62M
Total Debt	917.12M
Net Cash	-513.50M
Net Cash Per Share	-2.49
Equity (Book Value)	2.10B
Book Value Per Share	10.15
Working Capital	183.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -173.12 million and capital expenditures -372.96 million, giving a free cash flow of -546.08 million.

Operating Cash Flow	-173.12M
Capital Expenditures	-372.96M
Free Cash Flow	-546.08M
FCF Per Share	-2.64

Full Cash Flow Statement

Margins

Gross margin is -42.09%, with operating and profit margins of -73.27% and -79.71%.

Gross Margin	-42.09%
Operating Margin	-73.27%
Pretax Margin	-78.42%
Profit Margin	-79.71%
EBITDA Margin	-34.80%
EBIT Margin	-73.27%
FCF Margin	n/a

Dividends & Yields

Mycenax Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.99%
Shareholder Yield	-0.99%
Earnings Yield	-6.20%
FCF Yield	-6.29%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mycenax Biotech has an Altman Z-Score of 3.51.

Altman Z-Score	3.51
Piotroski F-Score	n/a